Mass Spectrometry-Based Systems Approach for Identification of Inhibitors ofPlasmodium falciparumFatty Acid Synthase

Antimicrobial Agents and Chemotherapy
2007.0

Abstract

The emergence of strains of Plasmodium falciparum resistant to the commonly used antimalarials warrants the development of new antimalarial agents. The discovery of type II fatty acid synthase (FAS) in Plasmodium distinct from the FAS in its human host (type I FAS) opened up new avenues for the development of novel antimalarials. The process of fatty acid synthesis takes place by iterative elongation of butyryl-acyl carrier protein (butyryl-ACP) by two carbon units, with the successive action of four enzymes constituting the elongation module of FAS until the desired acyl length is obtained. The study of the fatty acid synthesis machinery of the parasite inside the red blood cell culture has always been a challenging task. Here, we report the in vitro reconstitution of the elongation module of the FAS of malaria parasite involving all four enzymes, FabB/F (beta-ketoacyl-ACP synthase), FabG (beta-ketoacyl-ACP reductase), FabZ (beta-ketoacyl-ACP dehydratase), and FabI (enoyl-ACP reductase), and its analysis by matrix-assisted laser desorption-time of flight mass spectrometry (MALDI-TOF MS). That this in vitro systems approach completely mimics the in vivo machinery is confirmed by the distribution of acyl products. Using known inhibitors of the enzymes of the elongation module, cerulenin, triclosan, NAS-21/91, and (-)-catechin gallate, we demonstrate that accumulation of intermediates resulting from the inhibition of any of the enzymes can be unambiguously followed by MALDI-TOF MS. Thus, this work not only offers a powerful tool for easier and faster throughput screening of inhibitors but also allows for the study of the biochemical properties of the FAS pathway of the malaria parasite.

Knowledge Graph

Similar Paper

Mass Spectrometry-Based Systems Approach for Identification of Inhibitors ofPlasmodium falciparumFatty Acid Synthase
Antimicrobial Agents and Chemotherapy 2007.0
Design, Synthesis, and Biological and Crystallographic Evaluation of Novel Inhibitors of Plasmodium falciparum Enoyl-ACP-reductase (PfFabI)
Journal of Medicinal Chemistry 2013.0
Inhibitors of Nonhousekeeping Functions of the Apicoplast Defy Delayed Death in Plasmodium falciparum
Antimicrobial Agents and Chemotherapy 2007.0
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections
Bioorganic & Medicinal Chemistry 2010.0
2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes
Bioorganic & Medicinal Chemistry Letters 2014.0
Discovery of Bacterial Fatty Acid Synthase Inhibitors from a<i>Phoma</i>Species as Antimicrobial Agents Using a New Antisense-Based Strategy
Journal of Natural Products 2006.0
On-Bead Screening of a Combinatorial Fumaric Acid Derived Peptide Library Yields Antiplasmodial Cysteine Protease Inhibitors with Unusual Peptide Sequences
Journal of Medicinal Chemistry 2009.0
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening
European Journal of Medicinal Chemistry 2020.0
Design, Synthesis and Evaluation of Trisubstituted Thiazoles Targeting Plasmodium Falciparum Cysteine Proteases
Medicinal Chemistry Research 2005.0
Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors
MedChemComm 2011.0